When antibiotics first arrived, public discourse collapsed into two camps: penicillin as miracle, or penicillin as sin. Both were loud. Both were confident. Neither was asking the right question. Sound familiar?
Antibiotics rewrote what it meant to be vulnerable. Before them, a simple scratch could turn septic and kill a person in days. Penicillin, and the generations of broad-spectrums that followed, turned what had been fatal for millennia into something manageable: a course of pills and a week at home.
These wonder drugs also introduced effects that could not be seen: killing the targeted pathogen alongside the vital, protective bacteria the body needed to function. When deployed too broadly, too casually, or without a precise diagnosis, the biological environment adapted. The microbes evolved, developed resistance, and forced science into an endless arms race to engineer new defences.
But at the dawn of this medical revolution, during the roaring “Golden Age” of medicine, much of the conversation quickly stopped being about the illness. The entire world became utterly obsessed with the Drug.
Our public discourse split into two loud, hyper-focused factions that treated the compound as the main character of the era – casting it as either an omnipotent saviour or an existential sin, while completely ignoring the human organism it was being dropped into.
The first faction approached the Drug with uncritical, breathless worship. Before federal regulators stepped in to tighten prescription laws, a certain class of doctors began prescribing broad-spectrums for mild sniffles, pollen allergies, or vague complaints of seasonal malaise. They didn’t wait forty-eight hours for a lab culture to tell them exactly what microbe they were fighting – they had a crowded waiting room and a shiny new vial of tetracycline. They reached for the broad-spectrum because it made them feel like a wizard, kept the patients happy, and cleared the examination room in a few minutes.
Aggressive pharmaceutical companies quickly weaponized this desire for clinical throughput. They manufactured “shotgun therapies” – pre-mixed combinations that bundled heavy broad-spectrums with everyday vitamins, marketing them to physicians as defensive “wellness tonics.” Patients could bypass an exam room entirely, securing casual, phoned-in refills for any minor ailment, or a total lack thereof.
The second faction turned their total refusal of the Drug into a religion. An aggressive counter-culture movement emerged to fight the wonder-drug boom. Some naturopaths would watch a patient’s fever climb to dangerous limits and prescribe nothing but a strict water-fast and spiritual fortitude, terrified that a synthetic compound would corrupt the body’s “vital force.” They allowed patients to stay sick for weeks, clinging to the comforting logic that the old methods had eventually made them better, most of the time at least.
At the same time, external social critics, religious traditionalists, and institutional gatekeepers openly panicked that penicillin was effortlessly curing unseemly diseases. They were furious that science had stripped away the natural, biological punishment for risky behaviour, viewing the Drug as a dangerous cheat code that threatened the moral fabric of society. Their refusal became an unyielding identity – one that flatly declined to update with clinical progress because doing things “the hard way” felt natural.
Both factions skipped the nuance surrounding the Drug: what are we actually trying to treat, and is this the right thing to treat with?
But what if clinicians instead approached the Drug with care? What if they diagnosed properly, dosed correctly, monitored intelligently, and reconsidered when resistance inevitably appeared?
The vast, quiet majority weren’t fighting a holy war. They used the medicine pragmatically when a specific infection required it, and thoughtfully weighed the biases and risks that came with it. They operated on a completely different paradigm: the Diagnosis-Centric approach.
Even as the public shouting match raged, pioneering scientific voices were trying to direct the world’s attention toward the purpose of the Drug. As early as 1945, Alexander Fleming issued a stern behavioural warning: “The thoughtless person playing with penicillin treatment is morally responsible for the death of the man who finally succumbs to infection with the penicillin-resistant organism.” A decade later, microbiologist René Dubos also challenged the entire foundation of the boom from his laboratory at the Rockefeller Institute. Dubos warned that the total eradication of microbes was an illusion, arguing that lasting health required understanding the organism holistically.
Influenced by these warnings, a responsible practitioner slowed down. Before ever unscrewing a bottle, they asked what they were actually trying to treat, then worked rigorously to rule out common explanations first, select the narrowest compound, and evaluate how it would interact with the rest of the patient’s prescriptions and pre-existing conditions.
Furthermore, they forced themselves to look critically at the biases embedded in the meds sitting in their cabinets. They had to account for the fact that manufacturers frequently let aggressive marketing drown out their own warnings about severe side effects (e.g., the hidden risk of fatal bone marrow failure in heavily marketed broad-spectrums like chloramphenicol) just to protect a product line. They resisted the bundling of “shotgun therapies” and fought to find isolated molecules when the market only wanted to supply high-margin wellness packages. They had to carefully evaluate whether a glittering new brand name was a genuine scientific evolution or just a cheap generic molecule that a lab had cosmetically rebranded.
Armed with that awareness, diagnosis-centric practitioners researched new ways of distributing the Drug, alongside the resources doctors and patients needed to use it safely. They monitored systemic fallout and adjusted the moment the environment showed signs of resistance.
A decade later, the real-world consequences of the drug-centric debate finally became clear, and both extremes left a distinct scar on society.
On the side of the uncritical worshippers, the fallout was macro-biological. When researchers finally audited the prescribing data, the pattern was stark: for the colds, sore throats, and bronchitis that antibiotics do little or nothing to treat, doctors were writing antibiotic prescriptions upwards of 60 percent of the time. This systemic over-prescribing permanently altered the human microbiome and accelerated the global evolution of hyper-resistant superbugs.
On the side of the moral traditionalists and counter-culture deniers, the fallout was social. Their demonization didn’t stop the biology, but it manufactured shame around treatable illnesses and turned a clinical tool into a moral litmus test. Vulnerable patients were forced to choose between medicine and community, leaving them to suffer through conditions that a single prescription could have resolved.
The damage always fell on those whose problem the Drug was created to solve. The real breakthroughs came from those willing to experiment and learn.
We find ourselves in a strikingly familiar moment today, though we are dealing with a different kind of compound. The internet, the news, and boardrooms are currently locked in the exact same frantic, cure-it-all discourse.
Enthusiasts are slapping massive, generalized cognitive engines onto minor, everyday tasks – throwing billions of tokens at basic text formatting, minor data cleanup, or vague administrative tasks just to clear a queue and look progressive. Counter-culture refuses to touch the technology on fierce moral grounds, letting teams drown in hours of manual administrative sludge because they believe cognitive friction is the only way to preserve authentic human character.
Both sides are still entirely drug-centric, screaming at each other from opposite ends of a very narrow spectrum. Both sides have hot takes better shaped for airtime on social media, the news, and your company’s all-hands.
Meanwhile, a completely separate body of practitioners is quietly building on a different axis. At Attune, we realized early on that we cannot build a sustainable future without knowing what we’re solving for. AI is not our objective, nor is it a metric – it is a tool. When we built our business operating system within Claude Code, organizing six years of operational history and domain knowledge into navigable AI agents, we didn’t do it to become an “AI company.” We did it because we had a specific diagnostic need: we needed to give our team the structural breathing room to step above administrative sludge and focus on our actual mission of improving financial well-being, and AI happened to be the right solution for us.
There is no user manual for AI. There is still no consensus on what responsible use looks like in aggregate. As we try to figure out how to navigate this new penicillin, we have an obligation to stop shouting about the Drug and start focusing on the age-old diagnosis: what are we actually trying to solve, and is this the right tool to do it?
Build logs, system designs, and honest tool reviews from a small team building with AI. No spam. Unsubscribe anytime.
Check your email — a confirmation link is on the way.
Something went wrong. Please try again.